Drug Trial Radar · NCT03548207
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Jul 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
126
Actual
Start
Jun 29, 2018
Primary completion
Aug 23, 2022
Study completion Aug 23, 2022
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jun 7, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to characterize safety of JNJ-68284528 and establish the recommended Phase 2 dose (RP2D) (Phase 1b) and to evaluate the efficacy of JNJ-68284528 (Phase 2).
Conditions
- Multiple Myeloma
Interventions
JNJ-68284528Biological
JNJ-68284528 consist of autologous T lymphocytes transduced with LCAR-B38M, a lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1b: Number of Participants With Adverse Events as Per SeverityTime frame: Day 1 up to 45.2 months
- Phase 2: Overall Response Rate (ORR)Time frame: Day 1 up to 45.2 months
Locations
21 sites in 2 countries. Site status is shown where the registry gives one.
Mayo Clinic Cancer Center-Scottsdale
Phoenix, Arizona
City of Hope
Duarte, California
University of California San Francisco
San Francisco, California
University of Chicago
Chicago, Illinois
Dana Farber Cancer Institute
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan
Mayo Clinic Rochester
Rochester, Minnesota
University of Nebraska Medical Center
Omaha, Nebraska
Mount Sinai Medical Center
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Levine Cancer Institute
Charlotte, North Carolina
University of Pennsylvania
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Sarah Cannon Research Institute
Nashville, Tennessee
Froedtert Memorial
Milwaukee, Wisconsin
University Hospital Kyoto Prefectural University of Medicine
Kyoto, Japan
Nagoya City University Hospital
Nagoya, Japan
Hokkaido University Hospital
Sapporo, Japan
Japanese Red Cross Medical Center
Shibuya City, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.